An FDA approved therapy is proposed as a new therapeutic approach for GSD IV. A short-term rhGAA treatment significantly reduced liver glycogen content in GSD IV mice. rhGAA treatment alleviated liver disease progression in GSD IV mice. Our data suggests that rhGAA is a potential therapy for hepatic form of GSD IV.